Matches in Wikidata for { <http://www.wikidata.org/entity/Q80384676> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q80384676 description "artículu científicu espublizáu n'agostu de 2004" @default.
- Q80384676 description "im August 2004 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80384676 description "scientific article published on 01 August 2004" @default.
- Q80384676 description "wetenschappelijk artikel" @default.
- Q80384676 description "наукова стаття, опублікована в серпні 2004" @default.
- Q80384676 name "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in" @default.
- Q80384676 name "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in" @default.
- Q80384676 type Item @default.
- Q80384676 label "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in" @default.
- Q80384676 label "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in" @default.
- Q80384676 prefLabel "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in" @default.
- Q80384676 prefLabel "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in" @default.
- Q80384676 P1433 Q80384676-D316FFFB-D9F5-48AE-B6A5-7A9C4B318406 @default.
- Q80384676 P1476 Q80384676-1ABDF7DD-FC05-42E7-94D0-9CA46176A626 @default.
- Q80384676 P2093 Q80384676-136D05B2-7D92-452D-8323-886D3DEE5010 @default.
- Q80384676 P2093 Q80384676-1C1F02A8-A609-4ED4-B947-A1CB7A13CD87 @default.
- Q80384676 P2093 Q80384676-2A0E76E3-99C2-46C9-806B-A7447B6891DA @default.
- Q80384676 P2093 Q80384676-3FBA53A5-BDEC-45E2-A628-04B6C3D6F8F3 @default.
- Q80384676 P2093 Q80384676-909A0813-3B2E-4325-B4CC-5608933E1126 @default.
- Q80384676 P2093 Q80384676-94070AD6-DE7A-4E8D-96E3-9E88B7ECF8BA @default.
- Q80384676 P2093 Q80384676-9A203CCA-B271-424B-BFA3-8EC3BB406DBB @default.
- Q80384676 P2093 Q80384676-CA832B7C-4255-4C26-B5B3-A92196FEFB45 @default.
- Q80384676 P2093 Q80384676-D421A357-969D-45C9-AEBC-08C1F7B2B9CE @default.
- Q80384676 P2093 Q80384676-E9B9E865-D3EA-42C5-8929-89334E496240 @default.
- Q80384676 P2093 Q80384676-FF6EBD2F-1B4D-4AEA-87D8-C03FB6A6AC51 @default.
- Q80384676 P304 Q80384676-4F9172BC-8A94-4AE3-8200-840713E6223C @default.
- Q80384676 P31 Q80384676-E400C223-4F80-4E62-8D9D-C88B980C9EC5 @default.
- Q80384676 P356 Q80384676-A1336AC8-3762-416E-936F-93C40EAE45BD @default.
- Q80384676 P407 Q80384676-D20FD0D6-4D1B-4987-AD63-4DC09638B80D @default.
- Q80384676 P433 Q80384676-B692D639-1C77-4A8A-BFF2-9786119403F1 @default.
- Q80384676 P478 Q80384676-882D7F28-3BFD-42EA-892F-D36AE46F21D8 @default.
- Q80384676 P577 Q80384676-EB716AAA-9671-46BF-93A2-BA5CE53AA78E @default.
- Q80384676 P698 Q80384676-74C93DD9-5028-4592-939C-9A947A0C805A @default.
- Q80384676 P356 DIACARE.27.8.1897 @default.
- Q80384676 P698 15277414 @default.
- Q80384676 P1433 Q5270111 @default.
- Q80384676 P1476 "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease" @default.
- Q80384676 P2093 "Andrew J Palmer" @default.
- Q80384676 P2093 "Dick de Zeeuw" @default.
- Q80384676 P2093 "Hans-Henrik Parving" @default.
- Q80384676 P2093 "Lieven Annemans" @default.
- Q80384676 P2093 "Mark Lamotte" @default.
- Q80384676 P2093 "Pablo Lapuerta" @default.
- Q80384676 P2093 "Paulo Carita" @default.
- Q80384676 P2093 "Roger A Rodby" @default.
- Q80384676 P2093 "Roland Chen" @default.
- Q80384676 P2093 "Stéphane Roze" @default.
- Q80384676 P2093 "Sylvie Gabriel" @default.
- Q80384676 P304 "1897-1903" @default.
- Q80384676 P31 Q13442814 @default.
- Q80384676 P356 "10.2337/DIACARE.27.8.1897" @default.
- Q80384676 P407 Q1860 @default.
- Q80384676 P433 "8" @default.
- Q80384676 P478 "27" @default.
- Q80384676 P577 "2004-08-01T00:00:00Z" @default.
- Q80384676 P698 "15277414" @default.